To read this content please select one of the options below:

Risk Analysis for Merck and Company: Product KL-798

Publication date: 20 January 2017

Abstract

This case builds on the case "Merck & Company: Product KL-798" (UVA-QA-0582) by providing market uncertainties for the drug (drug quality, the presence of a competitor, market growth, and the time to the drug's release). Student and faculty spreadsheets are provided for the calculation of net present values for the scenarios. There is an additional challenge of how to treat the several downstream decisions (using OptQuest, for example) and how to value the license opportunity. A teaching note is also available to registered faculty members.

Keywords

Citation

Bodily, S.E. and Faulk, J. (2017), "Risk Analysis for Merck and Company: Product KL-798", . https://doi.org/10.1108/case.darden.2016.000262

Publisher

:

University of Virginia Darden School Foundation

Copyright © 2003 by the University of Virginia Darden School Foundation, Charlottesville, VA. All rights reserved.

Related articles